{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:35:39Z","timestamp":1790825739404,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.seminhematol.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T03:43:06Z","timestamp":1680061386000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-na\u00efve patients"],"prefix":"10.1053","volume":"60","author":[{"given":"Christian","family":"Buske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge\u202f\u202fJ.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma\u202f\u202fPrasad","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne\u202f\u202fO.","family":"Arulogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew\u202f\u202fR.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D'Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u202f\u202fJ.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"LeBlond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Leiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey\u202f\u202fV.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine\u202f\u202fS.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba\u202f\u202fK.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Tohidi-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine\u202f\u202fM.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Garcia-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios\u202f\u202fA.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven\u202f\u202fP.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2023.03.005_bib0001","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","article-title":"Treatment recommendations for patients with Waldenstr\u00f6m Macroglobulinemia and related disorders: IWWM-7 consensus","volume":"124","author":"Dimopoulos","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.03.005_bib0002","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1200\/JCO.2022.40.16_suppl.7566","article-title":"Bendamustine rituximab versus ibrutinib as primary therapy for Waldenstrom Macroglobulinemia: an International Collaborative Study","volume":"40","author":"Abeykoon","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.03.005_bib0003","first-page":"945","article-title":"Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstrom Macroglobulinemia","volume":"96","author":"Abeykoon","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0004","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1002\/ajh.26173","article-title":"Whimsical: a global Waldenstr\u00f6m's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes","volume":"96","author":"Tohidi-Esfahani","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0006","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom Macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m's Macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia","author":"Buske","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0008","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel\u2014an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk lymphoma"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0009","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom Macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0010","series-title":"Proc. Of the 11th International Workshop on Waldenstrom Macroglobulinemia","first-page":"39","article-title":"ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with waldenstr\u00f6m macroglobulinemia (wm)","author":"Dimopoulos","year":"2022"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0011","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstrom Macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0012","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2021.279112","article-title":"Natural history of Waldenstrom Macroglobulinemia following acquired resistance to ibrutinib monotherapy","volume":"107","author":"Gustine","year":"2022","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0013","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstrom Macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0014","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CARD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's Macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0015","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom Macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.03.005_bib0016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0017","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0018","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: Final analysis of a phase 2 study after a minimum follow-up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0019","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's Macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.005_bib0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstrom's Macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0021","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial Immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia: an Eastern Cooperative Oncology Group study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.03.005_bib0022","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's Macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0023","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against Sars-Cov-2: a prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0024","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.3390\/cancers14235816","article-title":"Low spike antibody levels and impaired ba.4\/5 neutralization in patients with multiple myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 booster vaccination","volume":"14","author":"Rosati","year":"2022","journal-title":"Cancers (basel)"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0025","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1182\/blood-2022-167899","article-title":"Clinical effectiveness and long-term serologic responses of COVID-19 vaccination in patients with multiple myeloma and Waldenstr\u00f6m Macroglobulinemia","volume":"140","author":"Branagan","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0026","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/HS9.0000000000000433","article-title":"Consensus statement on the management of Waldenstr\u00f6m Macroglobulinemia patients during the COVID-19 pandemic","volume":"4","author":"Talaulikar","year":"2020","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0027","series-title":"Proc. 11th International Workshop on WM, Madrid, Spain","article-title":"Presentation of STIL Maintenance Study of Rituximab in Waldenstrom Macroglobulinemia","author":"Rummel","year":"2022"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0028","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom Macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0029","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression risk stratification of asymptomatic Waldenstrom Macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0030","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-09-806463","article-title":"First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival","volume":"131","author":"Pika","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0031","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282264","article-title":"Light chain amyloidosis associated with Waldenstrom Macroglobulinemia: treatment and survival outcomes","author":"Gustine","year":"2022","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0032","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel Syndrome: a multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.03.005_bib0033","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.13883","article-title":"Central nervous system involvment by Waldenstrom macroglobulinemia (Bing Neel Syndrome): a multiinstitutional retrospective study","volume":"172","author":"Castillo","year":"2016","journal-title":"Br J Haem"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.005_bib0034","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.18202","article-title":"Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: a report of 64 patients","volume":"198","author":"Nivet","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0035","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I treat Waldenstrom Macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0036","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstrom Macroglobulinemia: an analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0037","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstrom Macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0038","article-title":"Ibrutinib and venetoclax in previously untreated Waldenstrom Macroglobulinemia","volume":"231","author":"Castillo","year":"2022","journal-title":"Proc Am Soc Hematology"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0039","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed \/refractory waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study","volume":"229","author":"Palomba","year":"2022","journal-title":"Proc Am Soc Hematology"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.005_bib0040","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0041","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/S2352-3026(18)30087-5","article-title":"Treatment and outcome patterns in European patients with Waldenstrom's Macroglobulinaemia: a large, observational, retrospective chart review","volume":"5","author":"Buske","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0042","article-title":"Treatment and survival outcomes of Waldenstrom Macroglobulinemia in Latin American patients: a multinational retrospective cohort study","volume":"8","author":"Riva","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0043","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstrom Macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0044","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0045","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom Macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"JClin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0046","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V126.23.1833.1833","article-title":"Long-term outcome of a prospective study of bortezomib, dexamethasone and rituximab (BDR) in previously untreated, symptomatic patients with Waldenstrom's Macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0047","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom Macroglobulinemia with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0048","first-page":"2772","article-title":"Long-term follow-up of a prospective clinical trial of carfilzomib, rituximab and dexamethasone (CARD) in Waldenstrom's macroglobulinemia","volume":"130","author":"Meid","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0049","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstrom Macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0050","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0051","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0052","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in waldenstrom's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0053","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom's Macroglobulinemia: final analysis from the randomized phase III INNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.005_bib0054","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.HS9.0000847388.33116.c7","article-title":"Acalabrutinib in treatment-naive or relapsed\/refractory Waldenstr\u00f6m Macroglobulinemia: 5-year follow-up of a phase 2, single-arm study","volume":"6","author":"Owen","year":"2022","journal-title":"HemaSphere"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:32Z","timestamp":1758522512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0037196323000264"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-na\u00efve patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}